Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 5Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Congenital Abnormalities 2Aggression 2Rectal Neoplasms 1Neoplasm, Residual 1GATA2 Deficiency 1

Interventions

Cyclophosphamide 7blinatumomab 6Cytarabine 6fludarabine 5Mercaptopurine 5Methotrexate 4fludarabine phosphate 3Vincristine 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Drug Therapy 3Dexamethasone 3Daunorubicin 3Asparaginase 3Whole-Body Irradiation 2Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Interleukin-2 2Doxorubicin 2Cladribine 2Blood Specimen Collection 2Azacitidine 2tisagenlecleucel 1thymoglobulin 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm, Residual × midostaurin × Clear all
NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡